RecruitingNot ApplicableNCT07330323

CARES : Customized Aftercare Report for Evaluated Skin Cancer Patients

Development and Evaluation of a Personalized Discharge Letter for Low-risk Skin Cancer Patients After Dermatological Screening.


Sponsor

Universitaire Ziekenhuizen KU Leuven

Enrollment

150 participants

Start Date

May 20, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Current clinical practices often provide general verbal advice to low-risk patients, which may not sufficiently address individual concerns or offer actionable steps. Generic information on the internet can be overwhelming or unreliable, leading to confusion and unnecessary follow-up visits. This project introduces a tailored approach by combining evidence-based guidelines with personalized details about the patient's risk profile. The discharge letter bridges the gap between clinical expertise and patient understanding, offering clear, specific, and actionable advice that has been shown to improve health behaviors and outcomes in other contexts . The personalized discharge letters are generated using an AI agent trained on validated letters from the hospital's electronic health record system (KWS). Each letter is reviewed and approved by a physician before being provided to the patient, ensuring both accuracy and clinical relevance.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria12

  • Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
  • Low-risk skin cancer patients:
  • Negative personal history for melanoma
  • Less than 100 naevi
  • Less than 5 clinically atypical naevi
  • Maximum 1 BCC in history
  • Maximum 1 SCC, and at least 5 years ago
  • AK: treated and controlled with clinical response
  • M Bowen: treated and controlled with clinical response
  • Adult subjects (between 18 years of age and 80 years) at time of enrolment
  • Any condition or comorbidity that, in the opinion of the investigator, may interfere with study participation or data interpretation (e.g. severe cognitive impairment, language barrier).
  • Participation in another interventional clinical trial that may interfere with the outcomes of this study.

Exclusion Criteria3

  • Presence of dermatological lesions requiring immediate treatment at the time of consultation.
  • History of solid organ transplantation (Organ Transplant Recipient, OTR).
  • Known carriers or suspected carriers (based on family history) of germline mutations associated with increased skin cancer risk (e.g. CDKN2A, PTCH1, XP genes).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALVerbal information only

Verbal information only

BEHAVIORALPersonalized Discharge Letter

Personalized Discharge Letter: Tailored written information based on individual risk profile, skin type and consultation findings.

BEHAVIORALPersonalized Discharge Letter + IntelliStudio

Personalized Discharge Letter + IntelliStudio: Tailored written information plus digital visual support (e.g. annotated images, visual summaries).


Locations(1)

UZLeuven, Department of Dermatology

Leuven, Vlaams-Brabant, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07330323


Related Trials